Notice of Intent to Publish a Funding Opportunity Announcement for Annual Conference in Therapeutics Development for Substance Use Disorders (U13 Clinical Trial Not Allowed)
Notice Number:
NOT-DA-25-033

Key Dates

Release Date:
October 29, 2024
Estimated Publication Date of Notice of Funding Opportunity :
December 18, 2024
First Estimated Application Due Date:
February 20, 2025
Earliest Estimated Award Date:
December 01, 2025
Earliest Estimated Start Date:
December 01, 2025
Related Announcements

None

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse, intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for a Conference Award to develop and implement an annual scientific meeting to advance the development of therapeutics for substance use disorders (SUDs). 

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

The NOFO is expected to be published in the Winter of 2024 with an expected application due date in early 2025.

This NOFO will utilize the U13 activity code. Details of the planned NOFO are provided below.

Research Initiative Details

This Notice encourages individuals with expertise and insights in the area of therapeutics development for substance use disorders (SUD) to begin to consider applying for this new NOFO when it is published. The purpose of the NOFO will be to support a Conference Award to develop and implement an annual scientific meeting that involves participants from patient advocacy organizations (PAO), academia, non-profit, industry, and government agencies such as NIDA and the FDA to advance the development of therapeutics for SUDs. The goal is to facilitate knowledge sharing, encourage communication by identifying and addressing common challenges faced by all sectors and leveraging each other’s expertise to find solutions, foster collaboration (e.g., developing joint projects), and facilitate transactions (e.g., licensing of compounds). 

The goal is to bring together all interested stakeholders that can contribute their knowledge and expertise to accelerate the development, FDA-approval, and commercialization of safe and effective treatments for SUDs.

Funding Information

Estimated Total Funding

$100,000

Expected Number of Awards

One

Estimated Award Ceiling

$100,000

Primary Assistance Listing Number(s)

93.279

Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

Iván Montoya, M.D., M.P.H.
Director, Division of Therapeutics and Medical Consequences (DTMC)
National Insitute on Drug Abuse (NIDA)
email: imontoya@nih.gov